Widespread white matter microstructural differences in schizophrenia across 4322 individuals: Results from the ENIGMA Schizophrenia DTI Working Group

Permalink
https://escholarship.org/uc/item/9w953844

Journal
Molecular Psychiatry, 23(5)

ISSN
1359-4184

Authors
Kelly, S
Jahanshad, N
Zalesky, A
et al.

Publication Date
2018-05-01

DOI
10.1038/mp.2017.170

License
CC BY 4.0

Peer reviewed
Widespread white matter microstructural differences in schizophrenia across 4322 individuals: results from the ENIGMA Schizophrenia DTI Working Group


1Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA; 2Harvard Medical School, Boston, MA, USA; 3Melbourne Neuropsychiatry Centre, Department of Psychiatry, University of Melbourne and Melbourne Health, Carlton South, VIC, Australia; 4Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; 5NORMENT, KG Jecesn Centre for Psychosis Research, Division of Mental Health and Addiction, Oslo University Hospital and Institute of Clinical Medicine, University of Oslo, Oslo, Norway; 6Department of Clinical Neuroscience, Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden; 7Department of Psychiatric Research, Diakonhjemmet Hospital, Oslo, Norway; 8University of Edinburgh, Edinburgh, UK; 9University of Oslo, Oslo, Norway; 10Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, SSGM, CIBERSAM, Madrid, Spain; 11Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy; 12Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 13Florey Institute of Neuroscience and Mental Health, Parkville, VIC, Australia; 14Department of General Practice, The University of Melbourne, Parkville, VIC, Australia; 15Swinburn University of Technology, Melbourne, VIC, Australia; 16Department of Psychiatry, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, The Netherlands; 17Neuroscience Research Australia and School of Psychiatry, University of New South Wales, Sydney, NSW, Australia; 18University of New Mexico, Albuquerque, NM, USA; 19The Department of Electrical and Computer Engineering, University of New Mexico, Albuquerque, NM, USA; 20The Mind Research Network, Albuquerque, NM, USA; 21Centre for Neuroimaging and Cognitive Genomics (NICOG), Clinical Neuroimaging Laboratory, NCBIES Galway Neuroscience Centre, National University of Ireland Galway, Galway, Ireland; 22Discipline of Psychiatry, School of Medicine, University of Queensland, Herston, QLD, Australia; 23Department of Computer Science and Engineering, The Ohio State University, Columbus, OH, USA; 24Beijing Huhuoguan Hospital, Beijing, China; 25Worldwide Research and Development, Pfizer, Cambridge, MA, USA; 26Santa Lucia Foundation, Rome, Italy; 27Department of Psychiatry, Seoul National University College of Medicine, Seoul, Republic of Korea; 28Department of Psychiatry and Neuropsychiatric Genetics Research Group, Institute of Molecular Medicine, Trinity College Dublin, Dublin, Ireland; 29Department of Psychiatry, VABHS, Harvard Medical School, Boston, MA, USA; 30Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 31Department of Psychiatry, University of Iowa, Iowa City, IA, USA; 32ABHNS, Harvard Medical School, Boston, MA, USA; 33Department of Psychiatry, Trinity College Dublin, Dublin, Ireland; 34Imaging Genetics Center, Stevens Neuroimaging & Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA, USA; 35Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 36Department of Psychiatry and Radiology, Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan; 37Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan; 38Department of Psychiatry, National Institute for Physiological Sciences, Aichi, Japan; 39Division of Cerebral Integration, National Institute for Physiological Sciences, Aichi, Japan; 40Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy; 41Laboratory of Neuropsychiatry, Department of Clinical and Behavioral Neurology, IRCCS Santa Lucia Foundation, Rome, Italy; 42Department of Psychiatry, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 43Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA; 44Zhuminan Psychiatry Hospital, Hennan Province, China; 45Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA; 46Molecular Research Center for Children’s Mental Development, United Graduate School of Child Development, Osaka University, Osaka, Japan; 47Department of Psychiatry, Osaka University Graduate School of Medicine, Osaka, Japan; 48Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; 49School of Electrical Engineering and Computer Science, University of Newcastle, Callaghan, NSW, Australia; 50Health Behaviour Research Group, University of Newcastle, Callaghan, NSW, Australia; 51National Institute of Mental Health, Kclecy, Czech Republic; 52Third Faculty of Medicine, Charles University, Prague, Czech Republic; 53University of Western Australia, Perth, WA, Australia; 54Erasmus University Medical Center, Rotterdam, The Netherlands; 55Laboratory for Neuroimaging, Department of Psychiatry, Psychosomatic Medicine and Psychotherapy, Goethe University, Frankfurt/Main, Germany; 56Brain and Mental Health Laboratory, Monash Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences and Monash Biomedical Imaging, Monash University, Clayton, VIC, Australia; 57Department of Psychiatry, Lausanne University Hospital (CHUV), University of Lausanne, Lausanne, Switzerland; 58Departments of Psychiatry and Radiology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA; 59Sunshine Coast Mind and Neuroscience Institute, University of the Sunshine Coast QLD, Australia, Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia; 60Department of Psychiatry, University of Minnesota, Minneapolis, MN, USA; 61Research Group in Psychiatry (GIPS), Department of Psychiatry, Faculty of Medicine, Universidad de Antioquia, Medellin, Colombia; 62Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; 63Department of Psychiatry, University of Iowa, Iowa City, IA, USA; 64ABHNS, Harvard Medical School, Boston, MA, USA; 65Department of Psychiatry, Trinity College Dublin, Dublin, Ireland;
The regional distribution of white matter (WM) abnormalities in schizophrenia remains poorly understood, and reported disease effects on the brain vary widely between studies. In an effort to identify commonalities across studies, we perform what we believe is the first ever large-scale coordinated study of WM microstructural differences in schizophrenia. Our analysis consisted of 2359 healthy controls and 1963 schizophrenia patients from 29 independent international studies; we harmonized the processing and statistical analyses of diffusion tensor imaging (DTI) data across sites and meta-analyzed effects across studies. Significant reductions in fractional anisotropy (FA) in schizophrenia patients were widespread, and detected in 20 of 25 regions of interest within a WM skeleton representing all major WM fasciculi. Effect sizes varied by region, peaking at (d = 0.42) for the entire WM skeleton, driven more by peripheral areas as opposed to the core WM where regions of interest were defined. The anterior corona radiata (d = 0.40) and corpus callosum (d = 0.39), specifically its body (d = 0.39) and genu (d = 0.37), showed greatest effects. Significant decreases, to lesser degrees, were observed in almost all regions analyzed. Larger effect sizes were observed for FA than diffusivity measures; significantly higher mean and radial diffusivity was observed for schizophrenia patients compared with controls. No significant effects of age at onset of schizophrenia or medication dosage were detected. As the largest coordinated analysis of WM differences in a psychiatric disorder to date, the present study provides a robust profile of widespread WM abnormalities in schizophrenia patients worldwide. Interactive three-dimensional visualization of the results is available at www.enigma-viewer.org.

Molecular Psychiatry (2018) 23, 1261–1269; doi:10.1038/mp.2017.170; published online 17 October 2017

INTRODUCTION

Schizophrenia, a debilitating psychiatric disorder with a considerable societal burden, has been a major focus of neuroimaging studies for decades, yet its neurobiology remains only partially understood. Cumulative evidence has led to a disconnection hypothesis—that schizophrenia may involve abnormal or inefficient communication between functional brain regions, and disturbances in the underlying pattern of white matter (WM) structural organization. Genetic and histopathological studies reveal oligodendrocyte and myelin abnormalities in schizophrenia. Furthermore, WM genetic variants have been found to overlap with genes associated with liability for schizophrenia. However, consistent alterations in WM microstructure have been difficult to identify. Diffusion tensor imaging (DTI) allows for the in vivo study of WM microstructural properties that cannot be made with standard magnetic resonance imaging alone. DTI has revealed WM changes beyond volumetric differences in unmedicated, first-episode and chronically affected schizophrenia patients, but the anatomical scope and strength of these effects varies widely across studies.

WM disruptions in DTI studies of schizophrenia patients are commonly identified, with significantly lower fractional anisotropy (FA) in patients compared with controls. Generally, findings have implicated prefrontal and temporal lobes, and the fiber tracts connecting these regions. Abnormalities have been linked to cognitive deficits and symptoms in schizophrenia, including memory impairment and auditory hallucinations. However, the considerable heterogeneity in both the effect sizes and the regional distribution of FA reduction reported across studies have limited the conclusions drawn to date. In a review by Kanaan et al., all studies included reported altered FA in schizophrenia patients, but the specific regions implicated were highly equivocal: each region implicated had a roughly equal chance of being identified versus not in a given study. It also remains unclear whether WM abnormalities are localized to specific tracts or distributed throughout the brain, and whether specific networks are differentially disrupted.

Sources of heterogeneity between studies may be attributed to imaging protocols, scanner differences, differences in patients’ ages at time of scanning, age at illness onset, duration of illness, symptom severity, medications and other variations in demographic and socioeconomic factors. Study samples also vary in size that alone may have a significant effect on the reported findings. These factors may modulate the degree of WM abnormalities detectable with DTI.

To address the variations in methods, and boost statistical power, the Schizophrenia Working Group of the Enhancing...
MATERIALS AND METHODS

Study samples

The ENIGMA-Schizophrenia DTI working group currently comprises 29 cohorts from 14 countries totaling 2359 healthy controls and 1963 individuals with schizophrenia (see Supplementary Figure 1). The mean age across samples was 36.14 years for controls (range: 18–86) and 36.22 years for patients (range: 18–77). Samples of controls and patients were ~53.4% and 67% males respectively, but effects of sex were also modeled. The mean age at onset and duration of illness across the patient groups were 23 and 14 years, respectively. The mean total Positive and Negative Syndrome Scale (PANSS) and Scale for the Assessment of Positive and Negative Symptoms (SANS) across the samples were 55.90, 16.72 and 13.70, respectively. For samples that recorded current antipsychotic type and dose, the fraction of patients on second-generation antipsychotics (atypical) was 71%, current antipsychotic type and dose, the fraction of patients on second-generation (typical) was 6%, both 10%, and neither 13%. As in van Erp et al., chlorpromazine (CPZ) equivalents were computed using methods previously described in Woods (2005; http://www.scottwilliwoods.com/files/Equivalent.doc). The mean CPZ dose equivalent across the samples was 371.23. Supplementary Tables 2 and 3 summarize key clinical and demographic information. Each study sample had been assessed with participants’ written informed consent approved by local institutional review boards. Individuals with bad-quality diffusion images were excluded from the analysis.

Imaging acquisition and processing

Details of study type, scanner and acquisition parameters for each of the 29 sites are provided in Supplementary Table 1. Preprocessing, including eddy current correction, echo-planar imaging-induced distortion correction and tensor fitting, was carried out at each site. Recommended protocols and procedures as well as quality control pipelines are available as part of the ENIGMA-DTI webpage and NITRC (Neuroimaging Informatics Tools and Resources Clearinghouse). Harmonization of preprocessing schemes was not enforced across sites to allow individual sites to use existing pipelines that may be more appropriate for their data acquisition. Once tensors were estimated, harmonized image analysis of DTI measure of FA was conducted at each site using the ENIGMA-DTI protocol (see Supplementary Note 1). As part of a secondary analysis, mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD) images were also derived. The present analysis combined ROIs across both hemispheres to avoid any potential issues of left/right flipping. Lateralized results are reported in Supplementary Table 4 and Supplementary Note 5 but should be interpreted with caution.

Statistical analysis

Per-site analysis. We evaluated FA, and available MD, AD and RD differences between schizophrenia cases and healthy controls by calculating Cohen’s d effect size estimates for diagnosis of schizophrenia in each of the 25 ROIs listed in Table 1. To tease apart regional WM effects from global differences, post hoc analyses were carried out to covary for the effects of global FA measures across the entire skeleton, including average FA across the full skeleton, the central, or ‘core’ FA comprising the average of all voxels in the JHU (Johns Hopkins University) ROIs, and the peripheral regions defined as everything besides the core (non-JHU) in the full skeleton analyzed (see Supplementary Note 2 for calculations of core and periphery FA). Cohen’s d effect sizes were also calculated for differences in FA between patients on atypical antipsychotics, typical antipsychotics, both and unmedicated. Differences in FA were assessed between subgroups of patients who were smokers versus nonsmokers. Multiple linear regressions were performed to examine the effects of age at onset, duration of illness, CPZ scores, PANSS total, positive and negative scores and SANS and SANS total scores. Age, sex, age-by-sex interaction and quadratic covariates of age and age by sex interaction were modeled as linear and nonlinear age and sex interactions have been reported for FA. As age and duration of illness are collinear, we also examined duration of illness in years without covarying for age, as well as duration expressed as the percent of a person’s lifetime they had been ill. Interaction effects, including diagnosis by sex and diagnosis by age, were also calculated. A minimum of 10 subjects per group was used as the cutoff for inclusion in the statistical analyses. An independent t-test between s.d. measures for average FA between patients (s.d. = 0.0176) and controls (s.d. = 0.0194) revealed no significant difference in variance between the groups (P > 0.05).

Meta-analysis

As in prior ENIGMA disease working group meta-analyses, a random-effects inverse-variance weighted meta-analysis was conducted at a central coordinating site (the University of Southern California Imaging Genetics Center) in R (metafor package, version 1.99–118 http://www.metafor-project.org/) to combine individual site effect sizes (See Supplementary Note 3). Heterogeneity scores (I²) for each test were also computed, indicating the percent of the total variance in effect size explained by heterogeneity of the effects alone. Lower values of I² indicate lower variance in the effect size estimates across studies. Effect sizes are reported as overall Cohen’s d values for case/control effects and Z-scores for quantitative effects from linear regressions. To control the reporting of false positives from multiple tests across the ROIs, for our primary analysis of FA differences in cases as compared with controls, effects were declared to be significant if they survived the Bonferroni correction threshold of 0.05/25 = 0.002.

RESULTS

FA differences between schizophrenia patients and controls

Of the 25 regions, 20 showed significantly lower FA in patients. Based on previous meta-analysis we hypothesized that FA tracts interconnected the frontal lobe, thalamus, cingulate gyrus and regions of the temporal lobe would be most severely affected. The largest effect size was observed for lower average FA (across the whole-brain WM skeleton) in schizophrenia patients, followed by the anterior corona radiata (ACR), the whole corpus callosum (CC), body of the CC and the genu of the CC (GCC). Significant patient reductions were also found in a further 15 ROIs (see Figure 1, Table 1 and Supplementary Figure 5).
MD and RD differences between schizophrenia patients and healthy controls

A secondary analysis was carried out using established measures of WM diffusivity (MD, AD and RD) for all 29 cohorts. Patients had significantly higher MD across 17 ROIs and significantly higher RD across 21 ROIs. Effects observed were larger and more widespread for RD. Finally, patients had significantly higher AD in the fornix in comparison with healthy controls (Figure 2; Supplementary Figures 6).

Sex differences

To examine differences between males and females in relation to diagnosis, sex-by-diagnosis interactions were conducted. Although we did not detect a significant interaction effect, we observed significant differences in effect size when analyzing males and females separately, with females showing significantly larger effects for decreased FA ($t = -10.83$, $P = 0.001$) in comparison with males, as seen through a paired $t$-test. See Supplementary Figures 10 and 11 and Supplementary Note 6.

Controlling for average, core and peripheral FA

To tease apart regional WM effects from the global differences, a post hoc analysis was conducted in individual tract ROIs (as previously performed) but additionally covarying for (1) average FA across the entire skeleton (the average FA contains both core and periphery voxels), (2) average FA within the core of the skeleton only, within which ROIs are defined as part of the JHU atlas or (3) the average FA within the periphery of the skeleton only—areas on the skeleton not included in the ROIs of the JHU atlas (non-JHU).

Covarying for average FA, there is significantly increased FA in the posterior limb of internal capsule (PLIC) only ($P < 0.002$). After covarying for core FA, there is significantly decreased average FA, body of corpus callosum, fornix, CC and anterior limb of internal capsule (ALIC), as well as increased FA in the PLIC ($P < 0.002$). Finally, after covarying for periphery FA, no effects remain significant after multiple comparison correction ($P < 0.05$), suggesting the effects are being driven by the peripheral WM regions and no individual ROI in the core of the WM goes significantly above and beyond those effects. See Supplementary Figures 2.

Association of clinical traits with FA

**Age by diagnosis.** To examine differences in the effects of age on FA between patients and controls, we performed age-by-diagnosis interaction tests for each ROI. A significant age-by-diagnosis interaction was observed in the ACR ($β = -0.00037$, $P = 0.00011$) and across the average FA skeleton ($β = -0.00018$, $P = 0.0003$), with patients showing accelerated FA reductions with age (see Supplementary Figure 12).

**Duration of illness and age at onset.** To investigate whether WM microstructure may change with illness duration, reflecting a progressive disease process, we conducted correlations between duration of illness and FA for patients across all ROIs. We found a significant inverse association between FA and duration of illness in years for 10 of the 25 ROIs (see Table 2), without age included in the regression model ($N = 1178$, 20 sites). When covarying for age, the relationship between duration of illness and FA is nonsignificant. No significant association between FA and duration of illness expressed as a percentage was observed. Similarly, no significant associations between FA and age at onset of schizophrenia were observed ($N = 1161$, 20 cohorts).

**Symptom severity.** To investigate whether WM changes were associated with positive and negative symptom severity in schizophrenia, we conducted correlations between symptom severity scores—as measured by PANSS positive, PANSS negative, SAPS and SANS—and FA across all ROIs. Trending negative correlations were observed between SAPS total scores ($N = 433$, 9 cohorts) and FA of the ALIC, CC, cingulum, IC and posterior thalamic radiation, as well as between SAPS total scores ($N = 406$, 9 cohorts) and FA of the CC and GCG, but the effects did not survive correction for multiple comparisons. Trending negative associations were also observed between PANSS negative ($N = 674$, 10 cohorts) scores in the ALIC, IFO, posterior thalamic radiation and SCC and PANSS total scores ($N = 695$, 10 cohorts) in the ALIC, CC, SCC and SCR. Similarly, these effects did not survive correction for multiple comparisons (see Supplementary Tables 5 and 6).

**Medication and smoking.** To assess the potential impact of antipsychotic medication on WM changes in schizophrenia, we carried out correlations between CPZ equivalent scores (Woods, 2005, http://www.scottwilliamwoods.com/files/Equivtext.doc) and FA. No significant associations between FA and CPZ scores were detected ($N = 627$, 10 cohorts). The current study was underpowered to compare patients based on their atypical or typical antipsychotic use in a multisite framework and therefore we decided to omit this from the analysis. Using a cutoff of $N = 10$ per group, only 31 patients from
two cohorts were taking both typical and atypical medication, 27 patients from 2 cohorts were taking typical antipsychotics only and 68 patients from 4 cohorts were unmedicated. The majority of patients (N = 486 across 10 cohorts) were taking atypical antipsychotics. Finally, to investigate the effects of nicotine intake on WM in schizophrenia, we examined differences between smokers and nonsmokers in the patient group. No significant differences in FA between smokers and nonsmokers in the patient group were observed. There were 248 nonsmoker patients and 260 smoker patients across 6 cohorts.

**DISCUSSION**

In the largest coordinated meta-analysis to date—evaluating DTI data from 1963 individuals with schizophrenia and 2359 healthy participants—we found a highly consistent pattern of affected WM in cohorts recruited around the world. FA was lower for patients globally across the whole-brain WM skeleton and significantly detected in 19 out of 24 tract-based ROIs, including the CC (specifically body and genu), the CR (anterior, posterior and superior), ALIC, fornix, posterior thalamic radiation, superior fronto-occipital fasciculus, sagittal stratum, cingulum, superior
The effect of RD is highly correlated, whereas axial diffusivity (AD) shows no correlation and low effect sizes.

### Table 2. Regression β-values, s.e. and P-values after meta-analysis for FA associations with duration of illness in years including sex as a covariate

<table>
<thead>
<tr>
<th>Region</th>
<th>Z-score</th>
<th>β-Value</th>
<th>s.e.</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>ACR</td>
<td>-4.04</td>
<td>-0.001013</td>
<td>0.00054</td>
<td>0.071</td>
</tr>
<tr>
<td>ALIC</td>
<td>-3.77</td>
<td>-0.000512</td>
<td>0.00041</td>
<td>1.66×10⁻⁹</td>
</tr>
<tr>
<td>Average FA</td>
<td>-7.08</td>
<td>-0.000476</td>
<td>0.00024</td>
<td>0.0094</td>
</tr>
<tr>
<td>BCC</td>
<td>-1.78</td>
<td>-0.001170</td>
<td>0.00024</td>
<td>9.33×10⁻¹⁰</td>
</tr>
<tr>
<td>CC</td>
<td>-3.34</td>
<td>-0.000836</td>
<td>0.00026</td>
<td>7.24×10⁻⁶</td>
</tr>
<tr>
<td>CGC</td>
<td>-7.67</td>
<td>-0.000761</td>
<td>0.00014</td>
<td>2.5×10⁻¹³</td>
</tr>
<tr>
<td>CGH</td>
<td>-4.58</td>
<td>0.000101</td>
<td>0.00020</td>
<td>0.65</td>
</tr>
<tr>
<td>CR</td>
<td>-4.19</td>
<td>-0.000702</td>
<td>0.00019</td>
<td>0.12</td>
</tr>
<tr>
<td>CST</td>
<td>-7.64</td>
<td>-0.000442</td>
<td>0.00013</td>
<td>0.95</td>
</tr>
<tr>
<td>EC</td>
<td>-6.14</td>
<td>-0.000528</td>
<td>0.00047</td>
<td>2.45×10⁻¹⁰</td>
</tr>
<tr>
<td>FX</td>
<td>-0.72</td>
<td>-0.000224</td>
<td>0.00011</td>
<td>0.0003</td>
</tr>
<tr>
<td>FXST</td>
<td>-1.90</td>
<td>-0.000673</td>
<td>0.00010</td>
<td>2.26×10⁻⁵</td>
</tr>
<tr>
<td>GCC</td>
<td>-3.42</td>
<td>-0.001011</td>
<td>0.00013</td>
<td>0.033</td>
</tr>
<tr>
<td>IC</td>
<td>-5.27</td>
<td>-0.000348</td>
<td>0.00045</td>
<td>0.11</td>
</tr>
<tr>
<td>IFO</td>
<td>-3.77</td>
<td>-0.000164</td>
<td>0.00063</td>
<td>0.72</td>
</tr>
<tr>
<td>PCR</td>
<td>-2.75</td>
<td>-0.000573</td>
<td>0.00008</td>
<td>0.0052</td>
</tr>
<tr>
<td>PLIC</td>
<td>-3.60</td>
<td>-0.000222</td>
<td>0.00057</td>
<td>0.4</td>
</tr>
<tr>
<td>PTR</td>
<td>-2.82</td>
<td>-0.001138</td>
<td>0.00011</td>
<td>3.03×10⁻⁷</td>
</tr>
<tr>
<td>RLIC</td>
<td>-3.87</td>
<td>-0.000584</td>
<td>0.00043</td>
<td>0.024</td>
</tr>
<tr>
<td>SCC</td>
<td>-5.02</td>
<td>-0.000600</td>
<td>0.00019</td>
<td>1.29×10⁻⁸</td>
</tr>
<tr>
<td>SCR</td>
<td>-2.80</td>
<td>-0.000499</td>
<td>0.00025</td>
<td>0.24</td>
</tr>
<tr>
<td>SFO</td>
<td>-3.05</td>
<td>-0.000599</td>
<td>0.00030</td>
<td>0.078</td>
</tr>
<tr>
<td>SLF</td>
<td>-6.76</td>
<td>-0.000600</td>
<td>0.00012</td>
<td>2.10×10⁻¹⁵</td>
</tr>
<tr>
<td>SS</td>
<td>-2.37</td>
<td>-0.000913</td>
<td>0.00009</td>
<td>2.62×10⁻²⁴</td>
</tr>
<tr>
<td>UNC</td>
<td>-0.65</td>
<td>-0.000871</td>
<td>0.00028</td>
<td>5.20×10⁻⁸</td>
</tr>
</tbody>
</table>

Abbreviations: ACR, anterior corona radiata; ALIC, anterior limb of internal capsule; BCC, body of corpus callosum; CC, corpus callosum; CGC, cingulum; CGH, cingulum (hippocampal portion); CR, corona radiata; CST, corticospinal tract; EC, external capsule; FA, fractional anisotropy; FX, fornix; FXST, fornix stria terminalis; GCC, genu of corpus callosum; IC, internal capsule; IFO, inferior fronto-occipital fasciculus; PCR, posterior corona radiata; PLIC, posterior limb of internal capsule; PTR, posterior thalamic radiation; RLIC, retrolenticular part of IC; SCC, splenium of corpus callosum; SCR, superior corona radiata; SFO, superior fronto-occipital fasciculus; SLF, superior longitudinal fasciculus; SS, sagittal stratum; UNC, uncinate. Significant regions (P < 0.05/25 = 0.002) are highlighted in bold.

In the context of a structural dysconnectivity hypothesis in schizophrenia, we were able to provide a more accurate estimate of WM alterations in the disorder. We analyzed data from 29 cohorts with a total sample of 4322 individuals using a common analysis pipeline we had previously developed. This allowed for a coordinated prospective meta-analysis of the data, unlike traditional meta-analyses that attempt to combine statistical results from the literature. This approach addresses, for we believe the first time, issues of low power and inconsistencies of analysis that have contributed to the heterogeneity and ambiguity in results of DTI studies in schizophrenia to date.
Demographic and clinical correlates of WM changes in schizophrenia

No significant sex-by-diagnosis interactions were observed in the current analysis, but females had significantly larger effect sizes for lower FA overall. Post-mortem studies suggest that WM abnormalities are more pronounced in female patients and an in vivo DTI analysis reported decreased FA in the CC for female patients compared with males. The etiology of these sex differences is unclear, but the findings suggest subtle sex-dependent alterations in WM in schizophrenia.

Duration of illness was negatively correlated with FA in 10 of the 25 WM ROIs. As duration of illness is highly correlated with age, these effects are hard to separate. After covarying for age, the relationship between FA and duration of illness is no longer significant. Longitudinal analyses of first-episode, high-risk, and chronic patients are needed to distinguish effects of age and duration of illness. Significant age-by-diagnosis interactions were found in the ACR and across the average FA. Unlike previous findings, Kochunov et al. report similar age-by-diagnosis interactions in these regions, indicating that schizophrenia patients are more susceptible to faster age-related decline in FA values of WM regions that mature later in life.

Trend-wise negative relationships between positive and negative symptom severity scores and WM FA of regions of the CC, IC and thalamic radiations were also observed. WM integrity of these regions has previously been associated with severity of positive, negative and cognitive symptoms. Parsing these measures based on the individual items of the positive and negative symptom scales may reveal more robust associations with WM FA. No significant effects of age at onset of schizophrenia or medication dosage were detected in the current study. Many cross-sectional DTI studies report no detectable correlations between medication and anisotropy.

Biological basis of WM abnormalities

This study confirms a brain-wide pattern of reduced FA and focal increased FA in schizophrenia, with the latter hypothesized to occur as a consequence of aberrant axonal pruning. By evaluating WM on a common skeleton, we are able to focus on microstructural differences independent of gray matter volumetric abnormalities. In comparing our findings with the ENIGMA-Schizophrenia study of subcortical volumes, we note that the maximal effect sizes are similar (Cohen’s $d \approx 0.4$), yet in that work, effects were found to be specific to certain subcortical structures including the hippocampus, amygdala and thalamus, whereas structures of the basal ganglia, including the caudate, putamen and pallidum, showed no effect. This implies more global deficiencies in WM whereas volume differences are more localized, perhaps in part because of the effect of added comorbidities. In a proof-of-concept work, Franke et al. were unable to find genetic overlap between schizophrenia and subcortical volumes. It is yet to be determined whether WM, which is more globally affected, may serve as a more promising endophenotype. Altered WM connectivity is postulated to play a significant role in the etiology of schizophrenia, but the mechanisms leading to altered connectivity remain unknown. Currently, hypotheses about the causative basis of this disconnection are varied and include changes in oligodendrocyte and microglial function. As noted above, age at onset, duration of illness (covarying for age) and medication dosage did not explain a significant proportion of WM variation, suggesting that whatever the causes, their effects do not overlap exclusively with the period of clinical diagnosis and treatment. However, WM deterioration may also be a consequence of the disorder. Copley et al. found that gray matter volume loss predated WM loss, with accelerated WM deterioration with age in schizophrenia, detecting significant WM differences in patients only detected after age 35. Furthermore, Pasternak et al. found increased free water—a potential surrogate marker for neuroinflammation—in first-episode schizophrenia, with deterioration in free-water corrected FA in chronic schizophrenia. These results may indicate that WM abnormalities may be more pronounced and more widespread in later stages of the illness and may be predated by gray matter volume loss and inflammation in earlier stages of the illness. Future analyses of these data sets will examine available samples of high-risk, first-episode, early and chronic schizophrenia to assess whether these WM effects are present before illness onset and whether they progress throughout the illness.

Study limitations

Despite being the largest of its kind, our study should be interpreted cautiously. This meta-analysis is cross-sectional and effects of age, age by diagnosis, along with durations of illness and/or medication exposure on WM microstructure may be more thoroughly investigated with a longitudinal design looking at rates of changes in the microstructural properties. The ENIGMA-DTI protocol has been validated for longitudinal analyses but follow-up assessments of patients with diffusion imaging are limited within the ENIGMA-Schizophrenia Working group cohorts. This current study is the first to show that effect sizes from harmonized DTI analyses may be pooled to detect reliable...
microstructural differences in patients from around the world. Future analyses aimed at harmonizing additional covariates across the ENIGMA groups may help tease apart effects. For example, accounting for genetic and environmental factors associated with schizophrenia, including general health conditions, lifestyle, additional recreational drugs or medications, trauma and stress, may add to a deepened understanding of the WM differences seen in this study.

In general, larger effects were observed in the larger ROIs containing a greater number of voxels, including the CC, and we found a medium but nonsignificant correlation between effect size and the square root of the number of voxels (sqrt(N)) in each ROI (see Supplementary Note 7). This is an issue that should be taken into consideration when interpreting regions where significant effects were not observed. As well as ROI size, we also investigated whether the number of gradient directions significantly affected Cohen’s d measures by splitting the cohorts into high direction (> 30 directions) and low direction (< 30 directions) groups. We found no significant differences in Cohen’s d measures between these groups (Supplementary Figure 9).

Lower FA in coherent fiber bundles may reflect abnormal fiber coherence or packing, or aberrations of axonal integrity and/or myelination. Although more detailed histopathological validations are needed, analyses of other diffusivity measures may help interpret the underlying microstructural abnormalities. Here we found widespread increased MD and RD in patients compared with controls, as well as increased AD in the fornix. This suggests that the observation of lower FA may be driven mainly by aberrant myelination across most ROIs, with axonal density reduction in the fornix, although these imaging-based estimates do not fully capture the underlying microscopic cellular processes to confirm this.

Finally, tract-based spatial statistics (TBSS) is a widely used method for voxel-based analysis of WM that addresses issues associated with smoothing and misalignment in DTI group analysis. However, the method has some limitations. TBSS reduces WM tracts into a skeleton, delineating the center of the tracts and projecting onto it only the highest value FA along the projection that results in loss of information and potential artifacts, often a result of misregistration. For example, as with any population study that spatially normalizes brain images, misalignment can occur; for TBSS however, this can be a particular problem in the separation of adjacent WM tracts. Smaller tracts, such as the fornix, are more susceptible to misalignment. Approaches for retrospective multisite analysis of DTI are extremely limited, yet we, as ENIGMA-DTI, have conducted several approaches for retrospective multisite analysis of DTI that will eventually allow for a large-scale cross-disorder comparison of disease effects on WM (for an overview of ongoing projects in ENIGMA, see http://enigma.usc.edu). Comparing WM effects will no doubt shed further light on similarities and differences in the pathophysiology of these disorders.

CONFLICT OF INTEREST

CSW is on an advisory board for Lundbeck, Australia Pty Ltd and in collaboration with Astellas Pharma Inc., Japan (no conflict of interest). The remaining authors declare no conflict of interest.

ACKNOWLEDGMENTS

Acknowledgments, funding sources, conflict of interest and author contributions can be found in Supplementary Note 8. GD’s research is generously supported by the European Research Council (grant no. 677467). CSW is funded by the NSW Ministry of Health, Office of Health and Medical Research. CSW is a recipient of a National Health and Medical Research Council (Australia) Principal Research Fellowship (PRF) #1117079.

REFERENCES

2 Friston KJ. Dysfunctional connectivity in schizophrenia. World Psychiatry 2002; 1: 66–71.
4 Konrad A, Winterer G. Disturbed structural connectivity in schizophrenia primary factor in pathology or epiphenomenon? Schizophr Bull 2008; 34: 72–92.
8 Bohlken MM, Brouwer RM, Mandl RCC, Kahn RSS, Hulshoff Pol HE. Genetic variation in schizophrenia liability is shared with intellectual ability and brain structure. Schizophr Bull 2016; 42: 1167–1175.


1629


37 Cassoli S, Guest PC, Malchow B, Schmitt A, Falkai P, Martins-de-Souza D. Disrupted macro-connectivity in schizophrenia linked to oligodendrocyte dysfunction: from structural findings to molecules. NPJ Schizophr 2015; 1: 15034.

